SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
MAY 3, 2005
GENOMED, INC.
-------------
(Exact name of registrant as specified in its charter)
FLORIDA 000-49720 43-1916702
----------------------------- ------------------ -----------------------
(State or other jurisdiction (Commission file (IRS Employer
of incorporation) number) Identification Number)
9666 OLIVE BLVD., SUITE 310, ST. LOUIS, MISSOURI 63132
------------------------------------------------------
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:
---------------------------------------------------
(314) 983-9933
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
(b) Effective May 3, 2005, the registrant has engaged Stark Winter Schenklin &
Co., LLP ("SWS") of Denver, Colorado, to serve as its independent
accountant to audit the registrant's financial statements.
SWS previously served as the registrant's independent accountant for the
fiscal years 2001-2004.
The registrant has not consulted SWS regarding the application of
accounting principles to a specific completed or contemplated transaction
or the type of audit opinion that might be rendered on the registrant's
financial statements, and no written or oral advice was provided by SWS on
any such issue that was a factor considered by registrant in reaching a
decision as to any accounting, auditing or financial reporting issue.
The registrant has not consulted SWS on any matter that was either the
subject of a disagreement or a reportable event with regard to the
registrant's prior auditors.
The registrant has provided a copy of the disclosure in this report to SWS
and offered SWS the opportunity to furnish a letter to the Commission
contemplated by Item 304(a)(2)(D) of Regulation S-K. SWS has advised that
is does not intend to furnish such letter to the Commission.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
GenoMed, Inc.
Dated: May 6, 2005 By: /s/ Dr. David Moskowitz
-------------------------------
Dr. David Moskowitz
Chairman of the Board and
Chief Executive Officer